Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

Although infrequent, primary biliary cholangitis is not indolent and remains a burdensome chronic autoimmune biliary disease. Progressive biliary injury and cholestasis results in complications of bil...

More than half of patients saw a biochemical response by 1 year with the novel oral agent

An EPICS-III study investigator discusses the mechanism of action of saroglitazar to treat patients with PBC.

Learning Objectives Upon completion of this program, participants will be able to: Apply current evidence to personalize treatment strategies for PwPBC​. Implement risk stratification and symptom…

Antimitochondrial antibody (AMA)-negative primary biliary cholangitis (PBC) is a rare presentation of PBC that comprises 5%–10% of all PBC patients. The pathogenesis of AMA-negative PBC appears to be similar to that of AMA-positive PBC. AMA-negative PBC presents similarly to AMA-positive PBC, with symptoms of cholestasis, fatigue, and pruritus most commonly reported. Defective bicarbonate production, resulting in acidification of bile and bile acids, has been proposed as the primary mechanism of damage to bile ducts and hepatocytes and is reflected in elevations of alkaline phosphatase and aminotransferases. Chronic damage can lead to the development of cirrhosis. The diagnosis is made by the finding of AMA negativity by ELISA or assays of similar sensitivity and a positive PBC-specific antinuclear antibody (ANA; anti-glycoprotein 210 and anti-speckled 100 kDa protein) test. In cases in which anti-glycoprotein 210 and anti-speckled 100 kDa protein assays are also negative, a liver biopsy is required to make the diagnosis after exclusion of other causes of cholestasis by magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography. Treatment for AMA-negative PBC is the same as for AMA-positive cases, with ursodeoxycholic acid as the first-line treatment. Current treatment is most effective in early stages, where it slows but does not eliminate progression. Risk stratification by validated tools such as the GLOBE and UK-PBC scores remains useful in AMA-negative PBC.

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by autoimmune-mediated destruction of intrahepatic bile ducts, leading to fibrosis, cirrhosis, and liver…

Primary biliary cholangitis (PBC) significantly impairs health-related quality of life (HRQL), yet the impact of disease stage and fatigue on HRQL and psychological status remains insufficiently quantified. This study aimed to investigate differences in HRQL across disease stages and the impact of fatigue in patients with PBC.